Pg. Johnston et al., THYMIDYLATE SYNTHASE EXPRESSION AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK-CANCER, Journal of the National Cancer Institute, 89(4), 1997, pp. 308-313
Background: Thymidylate synthase (TS), an essential enzyme in DNA synt
hesis, is a target for the fluoropyrimidines, an important group of an
tineoplastic agents used widely in the treatment of head and neck canc
er, Purpose: We evaluated relationships between the level and/or patte
rn of tumor TS expression and response to fluorouracil (5-FU)-based ne
oadjuvant chemotherapy in patients with advanced head and neck cancer,
Methods: Tumor specimens from 86 patients were available for this ret
rospective analysis, The patients were enrolled in four consecutive ph
ase II studies that tested combinations of 5-FU, leucovorin, and cispl
atin with or without added methotrexate plus piritrexim or interferon
alfa-2b (IFN alpha-2b), TS protein expression in the tumors was assess
ed by use of the TS 106 monoclonal antibody and standard immunohistoch
emical staining techniques, TS immunostaining was classified according
to its level of intensity (TS 0-1 = low, TS 2 = intermediate, and TS
3 = high) and according to its extent (focal pattern = less than 25% o
f tumor cells positive; diffuse pattern = greater than or equal to 25%
of tumor cells positive), Data from 79 patients were available for an
analysis of tumor TS expression and patient/tumor characteristics; 70
patients were assessable for their response to neoadjuvant chemothera
py. Results: There was a statistically significant association between
the level of tumor TS expression and the degree of tumor differentiat
ion; a higher proportion of patients whose tumors exhibited TS 0-1 imm
unostaining had undifferentiated or poorly differentiated tumors than
patients whose tumors exhibited TS 2 or TS 3 immunostaining (P = .03,
Jonckheere-Terpstra trend test), Among the 70 patients who were assess
able for response to neoadjuvant chemotherapy, TS 3 tumor immunostaini
ng was associated with a lower rate of complete response (i.e., comple
te disappearance of clinically detectable disease for a minimum of 4 w
eeks from time of initial determination) than was TS 2 or TS 0-1 immun
ostaining, but this association was not statistically significant (P =
.09, exact trend test); among the 39 patients who were treated with r
egimens that included 5-FU, leucovorin, cisplatin, and IFN alpha-2b, t
his inverse association between TS immunostaining intensity and respon
se was statistically significant (P = .02, exact trend test), Tumor TS
immunostaining intensity and overall survival were not found to be as
sociated, Patients with tumors exhibiting a focal pattern of TS immuno
staining have experienced significantly longer survival than patients
with tumors exhibiting a diffuse pattern; for the 53 patients with dif
fuse tumor TS immunostaining, the median survival was 24.7 months, whe
reas the median survival has not yet been reached for the 22 patients
with focal tumor TS immunostaining (P = .04, two-tailed logrank test),
However, the survival advantage for the focal versus diffuse TS immun
ostaining pattern was limited to patients whose tumors also exhibited
a TS 3 level of immunostaining intensity. Conclusions and Implications
: Characterization of tumor TS expression may he of value in identifyi
ng patients with advanced head and neck cancer who would benefit from
fluoropyrimidine-based neoadjuvant chemotherapy.